The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans.
Francesco MauraDavid G CoffeyCaleb K SteinEsteban BraggioBachisio ZicchedduMeaghen E SharikMegan T DuYuliza Tafoya AlvaradoChang-Xin ShiYuan Xiao ZhuErin W MeermeierGareth J MorganCarl Ola LandgrenPeter Leif BergsagelMarta ChesiPublished in: Nature communications (2024)
Multiple myeloma (MM) is a heterogeneous disease characterized by frequent MYC translocations. Sporadic MYC activation in the germinal center of genetically engineered Vk*MYC mice is sufficient to induce plasma cell tumors in which a variety of secondary mutations are spontaneously acquired and selected over time. Analysis of 119 Vk*MYC myeloma reveals recurrent copy number alterations, structural variations, chromothripsis, driver mutations, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide (APOBEC) mutational activity, and a progressive decrease in immunoglobulin transcription that inversely correlates with proliferation. Moreover, we identify frequent insertional mutagenesis by endogenous retro-elements as a murine specific mechanism to activate NF-kB and IL6 signaling pathways shared with human MM. Despite the increased genomic complexity associated with progression, advanced tumors remain dependent on MYC. In summary, here we credential the Vk*MYC mouse as a unique resource to explore MM genomic evolution and describe a fully annotated collection of diverse and immortalized murine MM tumors.
Keyphrases
- copy number
- transcription factor
- multiple myeloma
- signaling pathway
- mitochondrial dna
- crispr cas
- single cell
- high fat diet induced
- gene expression
- metabolic syndrome
- type diabetes
- multiple sclerosis
- oxidative stress
- genome wide
- skeletal muscle
- mesenchymal stem cells
- inflammatory response
- insulin resistance
- newly diagnosed
- cell proliferation
- bone marrow
- late onset
- early onset